Addition of Gallic Acid Overcomes Resistance to Cisplatin in Ovarian Cancer Cell Lines

Najwa Al Balushi¹, Syed Imran Hassan², Nada Abdullah¹, Buthaina Al Dhahi³, Shadia Al Bahlani³, Ikhlas Ahmed⁴, Benjamin K Tsang⁵, Sergey Dobretsov⁶, Yahya Tamimi⁷, Ikram A Burney¹

Abstract

**Objective:** Ovarian cancer is one of the leading causes of cancer-related mortality in women, and is often associated with drug resistance. Therefore, finding effective drugs, including naturally derived compounds, is urgently needed. Herein, we aimed to test the anti-cancer potential of gallic acid monohydrate (GA) and its congeners on cisplatin-sensitive (A2780S), and resistant (A2780CP) ovarian cancer and normal ovarian (HOSE6-3) cell lines. **Methods:** Cytotoxicity was assessed by AlamarBlue and CCK08 assays by exposing cells to different concentrations of cisplatin (0-21µg/mL), GA and its congeners (0-100µg/mL), and a combination of GA and cisplatin. Apoptosis was estimated by Hoechst stain and monitoring the relative RNA expression of the apoptotic effector caspase-3 using qRT-PCR. **Results:** GA decreased cell viability in a concentration-dependent manner in all cell lines, with an IC₅₀ of 19.39µg/mL (A2780S), 35.59 µg/mL (A2780CP), and 49.32µg/mL (HOSE6-3). GA displayed higher cytotoxicity than its congeners. An apoptotic rate estimation of approximately 20% and 30% was obtained in A2780S and A2780CP. While the cytotoxicity observed with cisplatin and GA was comparable, combining the two enhanced the cytotoxicity significantly, especially in the A2780CP cell line (p<0.05). **Conclusion:** These data suggest that GA may help overcome the resistance. Hence, the cytotoxic effects of GA, especially on chemo-resistant ovarian cancer cells merit further investigation.

**Keywords:** Ovarian cancer- gallic acid- cisplatin- cytotoxicity- chemo-resistance

Introduction

Ovarian cancer is the 8th most common cause of death from cancer among women worldwide and the 2nd most common cause of death from gynecological cancer (Bray et al., 2018). Epithelial ovarian cancer (EOC) accounts for 90% of all ovarian cancers, and high-grade EOC accounts for the majority (Kurman, 2014; Matulonis et al., 2016). The vast majority of patients with high-grade EOC are diagnosed with stage III/IV disease (Kurman, 2014). Debunking surgery and a combination of cisplatin and paclitaxel, with or without anti-angiogenic therapy has been the standard of care. However, the vast majority of patients experience a relapse of disease (Bristow et al., 2002; McGuire and Markman, 2003; du Bois et al., 2009; Markman, 2010; Burger et al., 2011; Perren et al., 2011). More recently, a small subset of patients with mutations in BRCA1 or BRCA2 gene or those with homologous recombination deficiency have been shown to respond to inhibitors of the poly (ADP-ribose) polymerase (PARP) enzyme, leading to a prolongation of disease-free survival (Konstantinopoulou et al., 2010; Ledermann et al., 2012; Oza et al., 2018). However, subsequently the disease becomes resistant to chemotherapy, including cisplatin. Despite the advances in treatment, the 5-year survival for stage III and IV disease remains 15-25% (Peres et al., 2018).
Gallic acid (GA, 3,4,5-trihydroxybenzoic acid) is a polyphenolic compound commonly found in many plants (Kakhkshani et al., 2019). Gallic acid has been reported to have anticancer activity against lung cancer (You and Park, 2010), breast cancer (Wang et al., 2014), prostate cancer (Kaur et al., 2009), leukemias (Madlener et al., 2007), and cervical cancer (You et al., 2010). Gallic acid was also reported to induce apoptosis in stomach cancer, colon cancer, adipocytes, and have an antiangiogenic effect in glioma cells (Yoshioka et al., 2000; Hsu et al., 2007; He et al., 2016; Sourani et al., 2016). Moreover, GA derivatives seem to have cytotoxic activities as well. For example, 3,4-Dihydroxybenzoic acid (Protocatechuic acid) was shown to exhibit an anti-proliferative effect on human gastric adenocarcinoma cells (Lin et al., 2007), while 4-Hydroxybenzoic acid derivatives were found to increase protein acetylation levels, arrest cell cycle progression, and subsequently trigger leukemia cells to programmed cell death without affecting the normal cells (Seidel et al., 2014).

In our previous study, the antitumor activity of 8 marine natural products and 32 extracts of marine organisms from Oman waters were studied (Dobretsov et al., 2016). Among the tested pure compounds, GA isolated from leaves of a mangrove tree Avicennia marina showed potent anticancer activity against the MCF-7 breast cancer cell line (Dobretsov et al., 2016). The inhibitory concentrations of GA against the MCF-7 cell line were >100 µg/mL. At the same time, GA at this concentration did not have quantifiable activity on the human fibroblast cells.

The primary objective of the present study was to assess the anti-cancer potential (cytotoxic activity) of GA monohydrate (7) and its congeners (3,4-dihydroxybenzoic acid (1), 3,5-dihydroxybenzoic acid (2), 4-hydroxybenzoic acid (3), 3-hydroxybenzoic acid (4), 3-fluoro-4-hydroxybenzoic acid (5), 4-fluoro-3-hydroxybenzoic acid (6) (Figure 1) on cisplatin-sensitive (A2780), cisplatin-resistant (A2780CP) ovarian cancer cell lines, and immortalized epithelial ovarian cell line (HOSE6-3). Also, the synergistic cytotoxic action of cisplatin and GA was examined on the cancer cell lines by exposing cells to both the agents simultaneously.

Materials and Methods

Reagents

GA monohydrate, C₆H₅(OH)⋅COOH⋅H₂O, M.W. = 188.14 g/mol, was purchased from Cica reagent, Kanto Chemicals, Japan. A stock solution of GA monohydrate (188.14 g/mol) was prepared in absolute ethanol (EMD Millipore) at 100 µg/mL and stored at 4°C. GA congeners (1-6, Figure 1) were purchased from AcrosOrganics, UK, as solid compounds and their solutions were prepared in absolute ethanol so that they were equivalent to 188.14 g/mol of GA monohydrate. Congeners are structurally related compounds, and congeners 1-6 and GA monohydrate (compound 7) are all derived from benzoic acid. The purity of compounds 1-7 was confirmed through TLC, and the structures were confirmed by NMR spectroscopy. 1H NMR was recorded on Jeol 400 MHz spectrometer. Chemical shifts (δ) are expressed in ppm. DMSO-d6 was used as a solvent, and tetramethylsilane (TMS) was used as the internal standard. Cisplatin was purchased from Mylan, USA as a 50 mg/mL solution.

1H NMR data of Gallic acid monohydrate (GA) and its congeners (1-6) are shown in Table S1 [see supplementary file].

Cell culture and treatment

Ovarian cancer cells sensitive (A2780S) and resistant to cisplatin (A2780CP) were provided by Prof. Benjamin K. Tsang from the University of Ottawa, Canada, and were maintained in Dulbecco’s Modified Eagle’s Medium, sodium pyruvate (Gibco). The A2780S cell line had been derived from a patient with a metastatic endometrioid type of ovarian carcinoma who had not been exposed to treatment. The cell line has epithelial morphology, and cells grow as a monolayer in tissue culture flasks. A2780CP was developed after repeated passages to cisplatin. Human ovarian surface epithelial cells (HOSE6-3) was provided by Prof. GSW Tsaw, from the University of Hong Kong, and was maintained in Minimum Essential Medium (MEM) (Gibco). All culturing media were supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin-streptomycin (Gibco) in a humidified incubator (5% CO₂) at 37°C.

Cell viability assay

AlamarBlue (Invitrogen, USA) and Cell Counting Kit-8 (CCK8 from Sigma-Aldrich) were used to determine the IC₅₀ of GA in A2780S, A2780CP and HOSE6-3 cell lines. Briefly, cells were cultured in a 96-well plate (Corning) at a density of 15,000 cells/well for 24h. The growth media was subsequently discarded and replaced with serum-free media and the cells were exposed to different concentrations of GA (0 µg/mL, 3.125 µg/mL(16.6µM) , 6.25 µg/mL(32.2 µM) , 12.5 µg/mL(66.4 µM) , 15.63 µg/mL(83 µM), 18.75 µg/mL(99.6 µM), 25 µg/mL(132.8 µM) , 28.125 µg/mL(149.4 µM), 31.25 µg/mL(166 µM), 34.375 µg/mL(182.7 µM), 37.50 µg/mL(199.3 µM), 40.625 µg/mL(215.7 µM), and 46.75 µg/mL(248.5 µM), 50 µg/mL(265.7 µM) and 100 µg/mL(53.15 µM) for 24h. A few wells were treated with an equal volume of ethanol used to prepare the different concentrations for the negative control. The corresponding absorbance was used in the calculation of the cell viability.

On the third day, the detection dye, AlamarBlue or CCK8 solution, was added. The plate was incubated for few hours (3hours with AlamarBlue and 1hour with CCK8), then read in a plate reader Multiskan spectrum (ThermoFisher Scientific, USA) 570/600 nm for AlamarBlue and 450/650 nm for CCK8. For consistency and statistical analysis, the viability of the control cells (untreated cells) was set at 100%, and experiments were repeated for three times.

Combination Index Calculation

To assess whether GA and cisplatin had a cytotoxic synergistic effect on A2780S and A2780CP cell lines, we...
used ComboSyn software (https://www.combosyn.com) to calculate the combination index (CI). Response to different doses of cisplatin and GA were used to generate a detailed report for each cell line (see supplementary file).

**Apoptosis Analysis**

Apoptosis was determined, as described previously (Al-Bahlani et al., 2017a; Al-Bahlani et al., 2017b). Briefly, A2780S and A2780CP cell lines were cultured in a 24-well plate (Corning) at a density of 150,000 cells/well and incubated overnight. Growth media was refreshed and different concentrations of GA (0 µg/mL, 3.125 µg/mL, 6.25 µg/mL, 12.5 µg/mL, 25 µg/mL, 50 µg/mL and 100 µg/mL) were added to cells and incubated for 24h. On the third day, cells were harvested, washed with Dulbecco’s phosphate-buffered saline, with no calcium and no magnesium (DPBS) (GIBCO, Thermo Fisher), stained with Hoechst 33258 dye (Sigma-Aldrich) in 10% formalin (1:50), and then preserved in the dark at 4°C until visualization (within 1-2weeks). Apoptotic cells were identified based on their morphology (smaller size and fragmented DNA) under a fluorescence microscope with a DAPI filter. We estimated the percentage of cells undergoing apoptosis by microscopic examination of different random fields at 40X and 100X magnification. We examined at least three different areas for each experiment, and the number of apoptotic cells was counted to estimate the percentage of survival. For consistency and accuracy, experiments were repeated three times.

**RNA extraction and qRT-PCR analysis**

RNA was extracted from cell lines using the PureLink RNA mini kit (Invitrogen). Briefly, cells were trypsinized in 0.25% trypsin-EDTA (Gibco), pelleted by centrifugation, and incubated in lysis buffer. 70% Ethanol was added to provide the appropriate binding of RNA to the silica membrane once the lysate was transferred into the RNeasy spin column. Columns were washed with washing buffer, and the RNA was eluted using RNase free water. 1µg of RNA was then reverse transcribed to make cDNA, using the high capacity cDNA reverse transcription kit following the manufacturer’s instructions (Applied Biosystems). Ten ng of cDNA and TaqMan pre-optimized probes were used to assess the gene expression of the caspase3 gene using qRT-PCR run on the 7500 fast real-time PCR machine (Applied Biosystems, Austin, TX). All obtained data were normalized to GAPDH expression, and the relative expression was obtained using the 2-ΔΔCT method. The experiment was repeated two times (in triplicate) separately.

**Western blotting**

Treated cells were harvested, and the pellet was washed in cold PBS (Dibco, US). Cells were lyzed in RIPA lysis buffer (Santa Cruz), supplemented with protease and phosphatase inhibitor cocktail (Thermo Scientific) in a concentration of 100:1. The obtained lysate was centrifuged at 4°C to remove any remaining cell debris, and the supernatant containing the proteins was subjected to Bradford assay for quantification. 50 µg of proteins were resolved on 10% SDS-PAGE for 90 minutes at 90V, then transferred to a PVDF membrane (Thermo Scientific) for 1 hour at 70V. The PVDF membrane was then blocked in 5% non-fat dry milk (BioRad) dissolved in 1X TBST for 30 minutes at room temperature. The blocked membrane was then exposed to primary antibody (1:1000 of β-actin mouse monoclonal antibody (Santa Cruz) and caspase3 rabbit monoclonal antibody (Abcam) at 4°C overnight. The membrane was then washed in 1X TBST three times for 5 min each, followed by exposing the membrane to HRP-conjugated secondary antibody (donkey anti-mouse IgG-HRP from Santa Cruz) (1:5,000 dilution) and anti-rabbit IgG-HRP (Cell Signaling). Membranes were then washed three times each for 5 min in 1X TBST before the revelation using the ECL kit (Thermo Scientific). The chemiluminescense signal was captured using the BioRad chemidoc touch imaging system, and proteins were quantified using ImageJ software. The experiment was repeated three times separately (Figures S1-S6).

**Statistical analysis**

All experiments were performed as triplicate and repeated at least three times independently. The results are reported as the mean ± standard deviation (SD). Means were compared using one-way ANOVA followed by a Tukey or Dunnett 2-sided post-hoc tests. Prior to analysis, the normality of the data and homogeneity of the variables were tested. The difference between means was considered significant at (*P < 0.05, **P < 0.01, ***P < 0.001).

**Results**

**Cell viability assays**

**Determination of IC_{50} in Cisplatin**

We used AlamarBlue and CCK8 reagents to assess cisplatin’s cytotoxicity in A2780S, A2780CP, and HOSE6-3 cell lines exposed to 9 different doses ranging from 0 to 21 µg/mL. A dose-dependent effect of cisplatin on the three cell lines is shown in Figure 2A. The difference in the viability of the cisplatin-treated cells, compared to the control, was statistically significant at doses more than 7.5 µg/mL for A2780S and HOSE6-3 cell lines. However, for A2780CP cells, significance was obtained only at 21µg/mL, which confirmed the resistance of A2780CP cells to cisplatin. The recorded IC_{50} values were 8.8 µg/mL (262µM), 9.4 µg/mL (103µM), and 23.1 µg/mL (189 µM) for HOSE6-3, A2780S, and A2780CP cell lines, respectively, as shown in Figure 2A.

**Determination of IC_{50} for GA**

The inhibitory effects of GA monohydrate against A2780S, A2780CP, and HOSE6-3 cell lines were determined using AlamarBlue and CCK8 cell viability assays. Figure 2B shows a dose-dependent cell viability inhibitory effect of GA against the three cell lines. The IC_{50} of GA was determined to be 19.39 µg/mL (103 µM), 35.59 µg/mL (189 µM), and 49.32 µg/mL (262 µM) for A2780S, A2780CP, and HOSE6-3 cell lines, respectively. Figure 2B shows the significant inhibition of cell growth at a concentration of 15.63 µg/mL in A2780S (p<8.3 E-06), 34.375 µg/mL (p<0.006) in A2780CP, but only weak inhibitory effect in HOSE6-3 (p<4.2 E-05). We
selected the IC\text{50} value for each cell line for subsequent experiments. We also exposed the three cell lines to the IC\text{50} of GA at different time points (6, 12, 24, and 48 hours). At 24 hours of exposure, all three cell lines showed a significant decrease in the viability (p<2.1E-08 for A2780S, p<4.5E-05 for A2780CP, and p<0.003 for HOSE6-3), and hence we chose the exposure time of 24 hours for subsequent experiments.

Cytotoxicity of GA and its congeners (1-6)

We then studied the cytotoxic effect of GA monohydrate and different congeners (1-6) using both AlamarBlue and CCK8 assays on the A2780S and A2780CP cell lines to determine the type of benzoic acid with the highest cytotoxicity. At 24 hours, GA monohydrate had the highest cytotoxic effect on A2780S (p<0.034 using CCK8 and p<2.9E-07 using AlamarBlue), and A2780CP cells (p<0.004 using CCK8 and p<1.7E-04 using AlamarBlue). In contrast, there was no significant change in cell death of A2780S and A2780CP when exposed to all other congeners (1-6) of GA (Figure 3). Therefore, the GA monohydrate was chosen for further analysis.

Synergistic effect of cisplatin and GA cytotoxicity

To determine whether a combination of cisplatin and GA would induce more cytotoxicity, the A2780S, and
A2780CP cells were exposed for 24 hours to cisplatin, GA, or a combination of cisplatin and GA using the IC\(_{50}\) values. There was no significant difference in the cell viability with either cisplatin or GA alone. However, when cisplatin and GA were applied together, the viability decreased in both cell lines (p<0.055 in A2780S and p<0.042 in A2780CP), with a much greater cytotoxicity being observed in A2780CP cells (Figure 4).

Moreover, the combination index revealed a synergistic effect of GA and cisplatin on A2780S cells at the IC\(_{50}\) doses (CI=0.3785 at IC\(_{50}\)). Similarly, a synergistic effect was obtained for GA and cisplatin on the A2780CP cell line (CI=6.5x10\(^{-6}\) at IC\(_{50}\)). The combination of GA and cisplatin had a synergistic effect at IC\(_{75}\), IC\(_{90}\), and IC\(_{95}\) values on both cell lines (see supplementary file for the combination index calculation).

**Apoptosis analysis**

Apoptosis was determined by exposing A2780S and A2780CP cells to different concentrations (0, 3.125, 6.25, 12.5, 25, 50, and 100 µg/mL) of GA for 24 hours and subsequently stained with Hoechst dye. Apoptosis was confirmed by morphological changes, including the fragmentation of nuclei and the smaller sized cells. The obtained apoptotic cell number seems to increase in a dose-dependent manner (Figure 5). The experiment was...
Caspase3 mRNA and protein expression in treated cell lines

qPCR data revealed that cell lines treated with cisplatin displayed the highest caspase-3 expression levels than cell lines treated with gallic acid, a combination of cisplatin/GA, and the control (Figures 6-8A). However, western blot analysis revealed different expression patterns of caspase3 in the cell lines, specifically A2780CP and HOSE6-3 cell lines (Figures 6-8B and C).

Caspase3 mRNA and protein levels were found higher in A2780S cells treated with cisplatin alone or combined with GA compared to the control (Figure 6A, B and C). Although increased content of caspase3 protein was evident in GA and cisplatin-treated cells, the difference did not reach significance compared to the control.

In the A2780CP cell line, cisplatin treatment was shown to promote apoptosis since caspase3 was highly expressed at mRNA and protein levels. In contrast, caspase3 expression in A2780CP cells treated with GA combined with cisplatin displayed higher mRNA abundance and lower protein content than controls (Figure 7A, B and C).

Immortalized normal epithelial ovarian cancer HOSE6-3 cells treated with cisplatin showed similar results to other cell lines, where expression of caspase3 at both mRNA and protein levels was significantly displayed. However, in GA and (GA + cisplatin) treated HOSE6-3 cells, lower expression than control was recorded by qRT-PCR, whereas Western blot analysis displayed higher levels than controls (Figure 8A, B and C).

Figure 6. The Level of Caspase3 in A2780S Control and Treated Cells with Cisplatin, GA, and Cisplatin Combined with GA. The relative caspase-3 mRNA abundance plot (A) resemble the data from two independent experiments while caspase-3 protein content data (B,C) were from three independent experiments. The Mann Whitney t-test was used to analyze all data. *P < 0.05, **P < 0.01
GA monohydrate produced significant cytotoxicity in cisplatin-sensitive and cisplatin-resistant cell lines. GA monohydrate was significantly more cytotoxic than the 6 congeners (1-6). GA produced cytotoxicity, at least in part, by inducing apoptosis. When compared with cisplatin, there was no significant difference in the cytotoxic activity; however, when cisplatin was added to GA, a significant increase in cytotoxicity was observed, suggesting synergistic action.

GA was selected for this study because our previous screening of anticancer compounds from Omani marine organisms demonstrated a potent cytotoxicity against the MCF-7 breast cancer cell line (Dobretsov et al., 2016). Commonly, GA is isolated from plant origin, but it is also found in seaweeds (Neethu et al., 2017; He et al., 2019; Wekre et al., 2019) and mangroves (Dobretsov et al., 2016). Cytotoxicity of GA has been demonstrated against the cancers of the lung (You and Park, 2010), prostate (Kaur et al., 2009), stomach (Lin et al., 2007), and the ovary (He et al., 2016). While, the anticancer activity of GA is not novel, anticancer activity of GA in combination with cisplatin, especially the synergistic effect against cisplatin-resistant ovarian cancer cell line, has been shown for the first time in this study.

To understand the effect of activating or deactivating groups on GA, compounds 1-6 were tested against the A2780S, A2780CP, and HOSE6-3 cell lines. The results showed that cytotoxicity decreases as the electron-donating OH group is removed or replaced with electron-withdrawing fluorine (F) group from the benzene ring (Figure 3 and Figure S7). The results also showed that...
the removal of OH group from the ring has no significant change in cytotoxicity. The cytotoxicity of all congeners (1-6) was comparable to each other. In congeners 1-6, benzene ring carries only one OH group either at position 3 or 4 or 5. Gallic acid (7) has three OH group at positions 3, 4, and 5 and this increases the cytotoxicity against A2780S cells and the least cytotoxic effect on the normal cell line HOSE6-3. These results are concordant with the previously reported GA selective inhibitory effect on ovarian cancer cell lines OVCAR-3 and A2780/CP70 compared to the normal IOSE-364 ovarian cell lines (He et al., 2016). The inhibitory effect of GA on the OVCAR-3 cells was more pronounced than the observed inhibition on A2780/CP70 cells. At 40 µM GA, A2780/CP70 viability was reduced to 30%, whereas on OVCAR-3, it was reduced to 2.1% (He et al., 2016). Also, 3,4-Dihydroxybenzoic acid was shown to decrease the proliferation of human gastric adenocarcinoma cells in a dose and time-dependent manner (Lin et al., 2007). However, human gastric adenocarcinoma cells were exposed to much higher doses of 3,4-Dihydroxybenzoic acid (0.5, 1.0, 2.0, 4.0, 6.0, and 8.0 mM), and IC₅₀ was approximately 7.3 mM (Lin et al., 2007), which is higher than the dose used in the present study (103 µM in A2780S and 189 µM in A2780CP).

Similarly, 4-Hydroxybenzoic acid derivatives were also tested on human K-562 leukemia cells and decreased the cell proliferation by approximately 20-40% at 100 µM dose after 24 hours of treatment (Seidel et al., 2014).

One of the major issues in the treatment of ovarian cancer is the resistance to platinum. Almost 80% of high-grade EOC respond to cisplatin at the time of diagnosis, and even at the time of relapse, if the relapse occurs more than one year after the last platinum dose (McGuire and Markman, 2003), called the platinum-sensitive relapse (Eisenhauer et al., 1997). Nevertheless, subsequently, almost all patients develop resistance to platinum compounds, and this is the major cause of ovarian cancer-related mortality. One of the important aims of the study was to see whether the addition of GA would overcome the resistance to cisplatin. Hence, a cell line was chosen with its cisplatin-resistant counterpart. The A2780 human ovarian cancer cell line was established from the tumour of an untreated patient with endometrioid cancer. The cisplatin-resistant cell line A2780CP was developed by chronic exposure of A2780 to cisplatin; A2780CP had a 6-7 fold resistance to cisplatin (IC₅₀ = 23.4 µM), compared with A2780S cells (IC₅₀ = 3.7 µM (Pan et al., 2002)). The mechanism underpinning this resistance is an increased activity of general efflux mechanisms, especially the intracellular copper ion transporters, ATP7A and ATP7B, which decrease the intracellular impact of cisplatin (Kalayda et al., 2008). It has been suggested that A2780CP is able to sequester and traffic the bound cisplatin to cellular lysosomes, away from genomic DNA (Kalayda et al., 2008). Protein profiling comparisons between cisplatin-sensitive parent strains and their resistant counterparts found similar proteomes between A2780 and A2780CP, suggesting the mechanism for cisplatin resistance occurs as part of post-translational modification (Zhu et al., 2005). Our results demonstrate that when cisplatin-sensitive and cisplatin-resistant cells were exposed to either cisplatin or GA, a modest degree of cytotoxicity was observed. However, when GA was added to cisplatin, cytotoxicity was significantly increased, especially in the cisplatin-resistant-cell line. There are several limitations of this study. While an increased cytotoxicity was observed in both A2780S and A2780CP cells treated with cisplatin combined with GA, the expression of caspase3 did not increase accordingly suggesting alternate mechanisms of GA-induced cytotoxicity. We did not check for the cleaved caspase-3 since the primary objective of this study was to show the effect of GA on the viability of cisplatin-resistant cells and whether adding GA to cisplatin will enhance cytotoxicity despite cisplatin resistance.

In conclusion, we report potent cytotoxic activity of GA in both cisplatin-sensitive and cisplatin resistant cell lines. Addition of GA to cisplatin increases the cytotoxicity. This suggests that addition of GA to cisplatin may be a potential treatment for cisplatin-resistant cancer patients, and is worth to be explored further.

Author Contribution Statement

IAB, YT, SIH, IA, SAB and SD made the concept and design of the study. NAB, NA, BAD, IAB, YT, SD, SAB, and SIH performed the investigation, data collection and analysis. NAB, IAB, YT, and SIH wrote the original draft. YT, IAB, SIH, SD, SAB and BKT did the critical revision of the manuscript. IAB, YT, and IA acquired funds for this project. BKT provides the cell line. All authors have read and approved the final manuscript.

Acknowledgments

Authors like to acknowledge Prof. GSW Tsaw, University of Hong Kong, for the generous gift of human ovarian surface epithelial cells (HOSE6-3).

Funding statement

This research was funded by His Majesty’s Trust Fund (HMTF) Oman, under grant number SR/MED/MEDE/17/01. This research is part of an approved PhD student (NA) thesis.

Availability of data and materials

The datasets generated and/or analysed during the current study are available from the corresponding author on request.

Ethics Approval

Not applicable. This study doesn’t require any ethical approval from the ethical committee.

Conflict of Interest

All the authors declare no conflict of interests.

References

Al-Bahlani S, Al-Lawati H, Al-Adawi M, et al (2017a). Fatty acid synthase regulates the chemosensitivity of breast cancer cells to cisplatin-induced apoptosis. Apoptosis, 22, 865-76.
Al-Bahlani SM, Al-Bulushi KH, Al-Alawi ZM, et al (2017b). Cisplatin Induces Apoptosis Through the Endoplasmic Reticulum-mediated, Calpain I Pathway in Triple-negative Breast Cancer Cells. Clin Breast Cancer, 17, e103-e12.

Bray F, Ferlay J, Soerjomataram I, et al (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394-424.

Bristow RW, Tomacruz RS, Armstrong DK, et al (2002). Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. J Clin Oncol, 20, 1248-59.

Burger RA, Brady MF, Bookman MA, et al (2011). Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. New Engl J Med, 365, 2473-83.

Dobretsov S, Tamimi Y, Al-Kindi MA, et al (2016). Screening for Anti-Cancer Compounds in Marine Organisms in Oman. SQUMJ, 16, 168-74.

du Bois A, Reuss A, Pujade-Lauraine E, et al (2009). Role of survival outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer, 115, 1234-44.

Eisenhauer EA, Vermorken JB, van Glabbeke M (1997). Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Ann Oncol, 8, 963-8.

He Y, Wang Y, Hu C, et al (2019). Dynamic metabolic profiles of 3,4-dihydroxybenzoic acid on human gastric carcinoma cells. Food Chem Toxicol, 1234-44.

Hsu C-L, Lo W-H, Yen G-C (2007). Gallic Acid Induces apoptosis by gallic acid in human stomach cancer KATO III and colon adenocarcinoma COLO 205 cell lines. J Agr Food Chem, 55, 7359-65.

Kahkeshani N, Farzaei F, Fotouhi M, et al (2019). Pharmacological effects of gallic acid in health and disease: A mechanistic review. Iran J Basic Med Sci, 22, 225-37.

Kalayda GV, Wagner CH, Buß I, et al (2008). Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer, 8, 175-86.

Kaur M, Velmurugan B, Rajamanickam S, et al (2009). Gallic Acid, an Active Constituent of Grape Seed Extract, Exhibits Anti-proliferative, Pro-apoptotic and Anti-tumorigenic Effects Against Prostate Carcinoma Xenograft Growth in Nude Mice. Pharm Res, 26, 2133-40.

Konstantinopoulos PA, Spentzos D, Karlan BY, et al (2010). Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer. J Clin Oncol, 28, 3555-61.

Kurman RJ, Carcangiu ML, Harrington CS, Young RH (2014). WHO Classification of Tumours of Female Reproductive Organs. , Geneva, Switzerland, WHO.

Ledermann J, Harter P, Gourley C, et al (2012). Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer. New Engl J Med, 366, 1382-92.

Lin H-H, Chen J-H, Huang C-C, et al (2007). Apoptotic effect of 3,4-dihydroxybenzoic acid on human gastric carcinoma cells involving JNK/p38 MAPK signaling activation. Int J Cancer, 120, 2306-16.

Madlener S, Ilmer C, Horvath Z, et al (2007). Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells. Cancer Lett, 245, 156-62.

Markman M (2010). Combination versus sequential cytotoxic chemotherapy in recurrent ovarian cancer: Time for an evidence-based comparison. Gynecol Oncol, 118, 6-7.

Matulonis UA, Sood AK, Fallowfield L, et al (2016). Ovarian cancer. Nat Rev Dis Primers, 2, 16061.

McGuire WP, Markman M (2003). Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer, 89, 3-8.

Neetu P, Suthindhiran K, Jayasri M (2017). Antioxidant and antiproliferative activity of Asparagusgopsis taxiformis. Pharmacognosy Res, 9, 238-46.

Oza AM, Matulonis UA, Malander S, et al (2018). Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol, 19, 1117-25.

Pan B, Yao K-S, Monia BP, et al (2002). Reversal of cisplatin resistance in human ovarian cancer cell lines by a-cjun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. Biochem Pharmacol, 63, 1699-707.

Peres LC, Cushing-Haagen KL, Köbel M, et al (2018). Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. J Natl Cancer, 111, 60-8.

Perren TJ, Swart AM, Pfisterer J, et al (2011). A Phase 3 Trial of Bevacizumab in Ovarian Cancer. New Eng J Med, 365, 2484-96.

Seidel C, Schneekenburger M, Diaco M, et al (2014). Antiproliferative and proapoptotic activities of 4-hydroxybenzoic acid-based inhibitors of histone deacetylases. Cancer Lett, 343, 134-46.

Sourani ZM, Pourghesari BP, Beshkar PM, et al (2016). Gallic Acid Inhibits Proliferation and Induces Apoptosis in Lymphoblastic Leukemia Cell Line (C121). Iran J Med Sci, 41, 525-30.

Wang K, Zhu X, Zhang K, et al (2014). Investigation of Gallic Acid Induced Anticancer Effect in Human Breast Carcinoma MCF-7 Cells. J Biochem Mol Toxic, 28, 387-93.

West EM, Käsin K, Underhaug J, et al (2019). Quantification of Polyphenols in Seaweeds: A Case Study of Ulva intestinalis. Antioxidants, 8, 612-27.

Yoshioka K, Kataoka T, Hayashi T, et al (2000). Induction of apoptosis by gallic acid in human stomach cancer KATO III and colon adenocarcinoma COLO 205 cell lines. Oncol Rep, 7, 1221-8.

You BR, Park WH (2010). Gallic acid-induced lung cancer cell death is related to glutathione depletion as well as reactive oxygen species increase. Toxicol In Vitro, 24, 1356-62.

Zhu K, Fukasawa I, Fujinoki M, et al (2005). Profiling of proteins associated with cisplatin resistance in ovarian cancer cells. Jpn J Cancer Res, 96, 535-43.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.